Healthcare

• EBITMarginexpanded to 74.9% in FY2026

• A$543 million in cumulative income disclosed in the September presentation

• Company continues focus on trophon ultrasound-probe disinfection systems

• Repaid US$25 million of NovaQuestDebtafterFacilitydrawdown

• FDA alignment confirmed on regulatory pathway for a New Drug Application

• EBIT rose 18.7% to A$582.9 million in the half-year result

According to the announcement, Actinogen's pivotal XanaMIA Phase 2b/3 trial, which is evaluating Xanamem in 247 patients with mild to moderate Alzheimer's disease across Australia and the United States, remained on track during FY26. The company said the trial had received three positive recommendations …